Cargando…

Identifying Serum Metabolomic Markers Associated with Skin Disease Activity in Patients with Psoriatic Arthritis

Psoriatic arthritis (PsA) is a chronic, systemic, immune-mediated inflammatory disease causing cutaneous and musculoskeletal inflammation that affects 25% of patients with psoriasis. Current methods for evaluating PsA disease activity are not accurate enough for precision medicine. A metabolomics-ba...

Descripción completa

Detalles Bibliográficos
Autores principales: Choksi, Hani, Li, Shenghan, Looby, Nikita, Kotlyar, Max, Jurisica, Igor, Kulasingam, Vathany, Chandran, Vinod
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10607811/
https://www.ncbi.nlm.nih.gov/pubmed/37894979
http://dx.doi.org/10.3390/ijms242015299
_version_ 1785127630896365568
author Choksi, Hani
Li, Shenghan
Looby, Nikita
Kotlyar, Max
Jurisica, Igor
Kulasingam, Vathany
Chandran, Vinod
author_facet Choksi, Hani
Li, Shenghan
Looby, Nikita
Kotlyar, Max
Jurisica, Igor
Kulasingam, Vathany
Chandran, Vinod
author_sort Choksi, Hani
collection PubMed
description Psoriatic arthritis (PsA) is a chronic, systemic, immune-mediated inflammatory disease causing cutaneous and musculoskeletal inflammation that affects 25% of patients with psoriasis. Current methods for evaluating PsA disease activity are not accurate enough for precision medicine. A metabolomics-based approach can elucidate psoriatic disease pathogenesis, providing potential objective biomarkers. With the hypothesis that serum metabolites are associated with skin disease activity, we aimed to identify serum metabolites associated with skin activity in PsA patients. We obtained serum samples from patients with PsA (n = 150) who were classified into mild, moderate and high disease activity groups based on the Psoriasis Area Severity Index. We used solid-phase microextraction (SPME) for sample preparation, followed by data acquisition via an untargeted liquid chromatography—mass spectrometry (LC-MS) approach. Disease activity levels were predicted using identified metabolites and machine learning algorithms. Some metabolites tentatively identified include eicosanoids with anti- or pro-inflammatory properties, like 12-Hydroxyeicosatetraenoic acid, which was previously implicated in joint disease activity in PsA. Other metabolites of interest were associated with dysregulation of fatty acid metabolism and belonged to classes such as bile acids, oxidized phospholipids, and long-chain fatty acids. We have identified potential metabolites associated with skin disease activity in PsA patients.
format Online
Article
Text
id pubmed-10607811
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-106078112023-10-28 Identifying Serum Metabolomic Markers Associated with Skin Disease Activity in Patients with Psoriatic Arthritis Choksi, Hani Li, Shenghan Looby, Nikita Kotlyar, Max Jurisica, Igor Kulasingam, Vathany Chandran, Vinod Int J Mol Sci Article Psoriatic arthritis (PsA) is a chronic, systemic, immune-mediated inflammatory disease causing cutaneous and musculoskeletal inflammation that affects 25% of patients with psoriasis. Current methods for evaluating PsA disease activity are not accurate enough for precision medicine. A metabolomics-based approach can elucidate psoriatic disease pathogenesis, providing potential objective biomarkers. With the hypothesis that serum metabolites are associated with skin disease activity, we aimed to identify serum metabolites associated with skin activity in PsA patients. We obtained serum samples from patients with PsA (n = 150) who were classified into mild, moderate and high disease activity groups based on the Psoriasis Area Severity Index. We used solid-phase microextraction (SPME) for sample preparation, followed by data acquisition via an untargeted liquid chromatography—mass spectrometry (LC-MS) approach. Disease activity levels were predicted using identified metabolites and machine learning algorithms. Some metabolites tentatively identified include eicosanoids with anti- or pro-inflammatory properties, like 12-Hydroxyeicosatetraenoic acid, which was previously implicated in joint disease activity in PsA. Other metabolites of interest were associated with dysregulation of fatty acid metabolism and belonged to classes such as bile acids, oxidized phospholipids, and long-chain fatty acids. We have identified potential metabolites associated with skin disease activity in PsA patients. MDPI 2023-10-18 /pmc/articles/PMC10607811/ /pubmed/37894979 http://dx.doi.org/10.3390/ijms242015299 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Choksi, Hani
Li, Shenghan
Looby, Nikita
Kotlyar, Max
Jurisica, Igor
Kulasingam, Vathany
Chandran, Vinod
Identifying Serum Metabolomic Markers Associated with Skin Disease Activity in Patients with Psoriatic Arthritis
title Identifying Serum Metabolomic Markers Associated with Skin Disease Activity in Patients with Psoriatic Arthritis
title_full Identifying Serum Metabolomic Markers Associated with Skin Disease Activity in Patients with Psoriatic Arthritis
title_fullStr Identifying Serum Metabolomic Markers Associated with Skin Disease Activity in Patients with Psoriatic Arthritis
title_full_unstemmed Identifying Serum Metabolomic Markers Associated with Skin Disease Activity in Patients with Psoriatic Arthritis
title_short Identifying Serum Metabolomic Markers Associated with Skin Disease Activity in Patients with Psoriatic Arthritis
title_sort identifying serum metabolomic markers associated with skin disease activity in patients with psoriatic arthritis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10607811/
https://www.ncbi.nlm.nih.gov/pubmed/37894979
http://dx.doi.org/10.3390/ijms242015299
work_keys_str_mv AT choksihani identifyingserummetabolomicmarkersassociatedwithskindiseaseactivityinpatientswithpsoriaticarthritis
AT lishenghan identifyingserummetabolomicmarkersassociatedwithskindiseaseactivityinpatientswithpsoriaticarthritis
AT loobynikita identifyingserummetabolomicmarkersassociatedwithskindiseaseactivityinpatientswithpsoriaticarthritis
AT kotlyarmax identifyingserummetabolomicmarkersassociatedwithskindiseaseactivityinpatientswithpsoriaticarthritis
AT jurisicaigor identifyingserummetabolomicmarkersassociatedwithskindiseaseactivityinpatientswithpsoriaticarthritis
AT kulasingamvathany identifyingserummetabolomicmarkersassociatedwithskindiseaseactivityinpatientswithpsoriaticarthritis
AT chandranvinod identifyingserummetabolomicmarkersassociatedwithskindiseaseactivityinpatientswithpsoriaticarthritis